Department of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany -
Department of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany.
Q J Nucl Med Mol Imaging. 2022 Sep;66(3):280-289. doi: 10.23736/S1824-4785.20.03224-0. Epub 2020 Jan 24.
Accuracy of [Ga]PSMA-11 PET/CT may be hampered by ureter accumulation, mimicking lymph node metastases depending on localization and configuration. The benefit of CT urography for differentiation of lymph node metastasis from urinary tract activity was evaluated in a "PET/CT with low-dose CT" setting.
Retrospective analysis of PET/CT for primary staging, biochemical recurrence or local treatment planning in patients with prostate cancer. For CT urography (CTU), iodinated contrast agent was administered 10 minutes prior to image acquisition. All potential pathologic (peri)ureteral tracer uptake was assigned to excretory ureteral accumulation or pathological lesion. To assess additional provided benefit of CTU all foci were rated with an introduced scoring system (ranging from 0 pts: CTU not needed; up to 3 pts: no differentiation possible without CTU). Success of ureter contrasting was assessed by measurement of Hounsfield units. Besides benefit for reading urography-enhanced PET/CT, the possible impact on subsequent patient treatment was evaluated.
A number of N.=247 patients were included in this study. By CT urography, it was possible to identify each ureter on low-dose CT, with its major part contrasted. In 120/247 (48.6%) patients, urography increased the diagnostic confidence while providing substantial support for interpretation in 60 (24.3%) cases. In 42 (17.0%) patients, urography was clinically relevant (up-/downstaging) with potential impact on subsequent patient care. In 30 of these 42 cases (12.1% of all), discrepant treatment would have resulted from a misdiagnosed tracer accumulation without urography.
CT urography benefits the interpretation of [Ga]-PSMA-11 PET/CT with low-dose CT and leads to discrepant patient treatment in a small but significant subset of patients (12% in our cohort). The implementation of CT urography into standard protocols of [Ga]PSMA-11 PET/CT with low-dose CT is recommended.
由于输尿管积聚,[Ga]PSMA-11 PET/CT 的准确性可能会受到影响,根据定位和配置,这些积聚可能类似于淋巴结转移。在“低剂量 CT 的 PET/CT”设置中,评估了 CT 尿路造影术 (CTU) 用于区分淋巴结转移和尿路活性的益处。
回顾性分析前列腺癌患者的原发性分期、生化复发或局部治疗计划的 PET/CT。对于 CTU,在图像采集前 10 分钟给予碘造影剂。将所有潜在的(周围)输尿管示踪剂摄取分配给排泄性输尿管积聚或病理性病变。为了评估 CTU 提供的额外益处,使用引入的评分系统对所有焦点进行评分(范围为 0 分:不需要 CTU;高达 3 分:没有 CTU 无法区分)。通过测量亨氏单位评估输尿管对比度增强的效果。除了对阅读尿路增强 PET/CT 的益处外,还评估了对后续患者治疗的可能影响。
本研究共纳入 N=247 例患者。通过 CTU,可以在低剂量 CT 上识别出每个输尿管及其主要部分的对比。在 120/247(48.6%)例患者中,CTU 提高了诊断信心,并在 60(24.3%)例患者中为解释提供了实质性支持。在 42(17.0%)例患者中,CTU 具有临床意义(上下分期),并可能对后续患者治疗产生影响。在这 42 例中有 30 例(所有患者的 12.1%),如果没有 CTU,则误诊的示踪剂积聚会导致治疗不一致。
CTU 可改善低剂量 CT 的[Ga]-PSMA-11 PET/CT 解读,并导致一小部分患者(我们队列中的 12%)出现治疗不一致。建议将 CTU 纳入低剂量 CT 的[Ga]PSMA-11 PET/CT 标准方案中。